Supported by Pfizer, this flagship initiative aims to improve awareness, recognition, and clinical management of cancer cachexia among healthcare providers across the United States. Cancer cachexia remains significantly under-recognized despite its major impact on survival, treatment tolerance, and quality of life for patients living with cancer. Through this initiative, eHealthyInfo is developing high-quality, evidence-based educational content, including clinician-focused video modules and clinically relevant infographics for real-world practice. The educational materials address early identification of cachexia, its clinical consequences, emerging biomarkers such as GDF-15, and evidence-based management approaches including supportive care and clinical trial considerations.
Goal: To improve early recognition, clinical decision-making, and patient outcomes related to cancer cachexia in oncology practice.